FDA drug recalls
Formal FDA enforcement reports for prescription and over-the-counter drugs — contamination, wrong potency, mislabeling, and manufacturing failures. 341 recalls in the last 12 months, in plain English.
Recent recalls
Page 5 of 12- Victory Medical Center glutathione recalled for microbial contamination
Victory Medical Center Pharmacy's Glutathione injectable solution (200 mg/mL) failed sterility testing and was found to contain elevated bacterial endotoxin levels, which are out of acceptable limits. The affected product was distributed nationwide in specific lots with expiration dates through August 2026.
SeriousFDAAug 19, 2026Victory Medical Center Pharmacy
- Kian Pee Wan Capsules recalled for undeclared dexamethasone, cyproheptadine
Buy-Herbal's Kian Pee Wan Capsules contain two prescription drug ingredients—dexamethasone and cyproheptadine—that are not listed on the label and were not approved by the FDA. The product was sold online through eBay. No injuries have been reported.
SeriousFDAAug 19, 2026Buy-Herbal
- Heritage clindamycin oral solution recalled for foreign substance
Heritage Pharmaceuticals' clindamycin palmitate hydrochloride oral solution (75 mg/5 mL) has been recalled due to the presence of particles and white flakes found in reconstituted bottles. The affected lot is 2411550, which expires November 2026. This product was distributed nationwide.
ModerateFDAAug 19, 2026Heritage Pharmaceuticals
- Clear Eyes Maximum Itchy Eye Relief recalled for potential contamination
CLEAR EYES Maximum Itchy Eye Relief eye drops may not be sterile due to potential contamination. The affected product is the 0.5 fl oz (15 mL) dropper bottle, Lot 2552A with expiration date 09/30/2027. No injuries have been reported.
ModerateFDAAug 19, 2026Prestige Brands
- Shoolin Pharma sildenafil and tadalafil powders recalled for manufacturing violations
Shoolin Pharma Chem LLP is recalling five bulk powder products, sildenafil citrate and tadalafil in 100-gram, 500-gram, and 1-kilogram sizes, sold for prescription compounding only. The recall was triggered by manufacturing practice (CGMP) deviations found during an FDA inspection, and no injuries have been reported. The products were distributed nationwide.
ModerateFDAAug 19, 2026Shoolin Pharma Chem5 products
- Apollo Care semaglutide vials recalled for particulate matter
Apollo Care is recalling 11 strengths of semaglutide sterile multi-dose vials for subcutaneous injection, all sold under the APOLLO care brand. The vials may contain particles identified as nylon/polyamide and silk-like material. The recall covers products distributed nationwide, and no injuries have been reported.
ModerateFDAAug 19, 2026Apollo Care11 products
- Diovan 160 mg tablets recalled for failed dissolution specifications
One lot of Novartis Diovan (valsartan) 160 mg tablets failed to meet dissolution specifications, which means the tablets may not dissolve properly in the body. This could affect how well the medication works. The affected lot (AV5913C, expiring 6/2027) was distributed nationwide.
ModerateFDAAug 19, 2026Novartis
- Zydus mirabegron extended-release tablets recalled for N-nitroso impurity
Zydus Pharmaceuticals is recalling one lot of Mirabegron Extended-Release 25 mg tablets due to higher-than-acceptable levels of N-Nitroso Mirabegron impurity. This impurity can potentially increase long-term health risks with continued use. No injuries have been reported.
ModerateFDAAug 12, 2026Zydus
- Sunny Pharmtech cyclophosphamide recalled for stainless steel particulate
Cyclophosphamide for Injection, USP (1 gram/vial) manufactured by Sunny Pharmtech Inc. for Long Grove Pharmaceuticals may contain stainless steel particulate matter. The contamination was identified in two specific lots before distribution was completed.
SeriousFDAAug 12, 2026Sunny Pharmtech2 products
- Central Admixture pediatric TPN bags recalled for formulation error
Central Admixture Pharmacy Services Inc. has recalled two patient-specific pediatric Total Parenteral Nutrition (TPN) bags due to incorrect product formulation. The affected bags were compounded with the wrong nutrient mixture. The recall affects only two prescriptions distributed in Georgia with lot numbers 20-1535990-0-1 and 20-1535892-0-1 (expiration July 16, 2026).
ModerateFDAAug 12, 2026Central Admixture Pharmacy Services
- Aurobindo Dicyclomine capsules recalled for empty capsules
Aurobindo Pharma USA is recalling Dicyclomine Hydrochloride Capsules 10mg (Batch DMC125018A, expiration 07/2027) because some bottles contain empty capsules instead of the medication. The issue affects approximately 6,408 bottles distributed nationwide.
ModerateFDAAug 12, 2026Aurobindo Pharma
- Ascend dabigatran capsules recalled for failed impurity specification
Ascend Laboratories is recalling one lot of dabigatran etexilate 150 mg capsules. Stability testing at 12 months found out-of-specification results for Impurity II, Impurity III, and total impurities. No injuries have been reported.
FDAAug 5, 2026Ascend Laboratories3 products
- Mylan mycophenolate mofetil injection recalled for precipitate
Mylan Pharmaceuticals is recalling one lot of mycophenolate mofetil for injection vials because of the presence of precipitate, which is solid material that has separated out of the liquid. The recall covers 5,688 single-dose vials distributed nationwide. No injuries have been reported.
ModerateFDAAug 5, 2026Mylan
- Glenmark azelaic acid gel recalled for abnormal texture
Glenmark Pharmaceuticals is recalling certain lots of Azelaic Acid Gel, 15%, 50-gram tubes, after customers reported grainy, gritty, or sandy texture. The FDA classifies this as a quality problem with the product's manufacturing process. No injuries have been reported.
ModerateFDAAug 5, 2026Glenmark
- Micro Labs dorzolamide-timolol eye drops recalled for container defect
Micro Labs USA Inc. recalled dorzolamide HCl and timolol maleate ophthalmic solution (2%/0.5%, 10 mL bottle) because the firm received complaints of broken cap spikes and undeliverable drops. The notice reports no injuries.
ModerateFDAAug 5, 2026Micro Labs USA
- Trokendi XR topiramate capsules recalled for failed dissolution
Supernus Pharmaceuticals is recalling one lot of Trokendi XR (topiramate extended-release capsules, 25 mg, 30 count) because it failed dissolution specifications. The FDA has classified the recall as Class III, and no injuries have been reported.
ModerateFDAJul 29, 2026Supernus
- Bionpharma divalproex sodium tablets recalled for foreign tablets
Bionpharma Inc. is recalling 500 mg divalproex sodium delayed-release tablets because the bottles have foreign tablets or capsules in them. No injuries have been reported. The recall covers one lot sold nationwide.
ModerateFDAJul 29, 2026Bionpharma
- Ascend dabigatran capsules recalled for failed impurity tests
Ascend Laboratories is recalling dabigatran etexilate capsules, 110 mg, after an out-of-specification result in 12-month long-term stability testing for Impurity II, Impurity III and total impurities. This means the product failed its impurity specifications. No injuries have been reported.
FDAJul 29, 2026Ascend Laboratories2 products
- JB Chemicals cetirizine tablets recalled for ranitidine cross-contamination
Customers reported discolored cetirizine tablets with red dots. The agency determined the red dots to be ranitidine, which is a cross-contamination from other products. The recall covers Cetirizine Hydrochloride Tablets USP 5 mg, 100-count bottles, made by Unique Pharmaceuticals Labs and distributed by Rising Pharma Holdings.
SeriousFDAJul 29, 2026JB Chemicals
- Fresenius Kabi Xylocaine, Naropin and more recalled over hair
Fresenius Kabi is recalling five injectable medicine products because hair was found in some vials. The products are Xylocaine (two sizes), Naropin, lidocaine HCl injection and glycopyrrolate injection, all made by Fresenius Kabi in Lake Zurich, Illinois, and sold nationwide. No injuries have been reported.
ModerateFDAJul 29, 2026Fresenius Kabi5 products
- Rising cyproheptadine syrup recalled for precipitate in bottle
Rising Pharma's Cyproheptadine Hydrochloride Syrup (2 mg/5 mL, 473 mL bottles) is being recalled because the medication is crystallizing and forming particles that float in the bottle. This affects specific batches distributed nationwide. No injuries have been reported.
ModerateFDAJul 29, 2026Rising Pharma
- Rohto Cooling Eye Drops recalled for sterility concerns
Rohto-Mentholatum is recalling eight Rohto Cooling Eye Drops products because they lack assurance of sterility, meaning the drops may not be guaranteed free of microbial contamination. All eight are sold under the Rohto Cooling Eye Drops name: ALL-IN-ONE, Max Strength (three versions), Optic Glow, Digi Eye, Dry Aid (single and twin pack), and Cool Relief. No injuries have been reported.
ModerateFDAJul 29, 2026Rohto-Mentholatum8 products
- Asclemed Lidolog Kit recalled for barcode label issue
Asclemed USA Inc. is recalling Lidolog Kit, which contains lidocaine injection, because the label wrap covers the barcode, making it difficult to scan. This labeling defect affects 18 kits distributed in Tennessee.
FDAJul 29, 2026Asclemed
- Ascend amlodipine and olmesartan tablets recalled for failed dissolution
Ascend Laboratories is recalling one lot of amlodipine and olmesartan medoxomil combination tablets (10 mg/20 mg) because the olmesartan medoxomil active ingredient is below the required amount. This means affected tablets may not work as intended to lower blood pressure.
ModerateFDAJul 29, 2026Ascend Laboratories
- Major Pharmaceuticals levothyroxine 25 mcg recalled for subpotency
Major Pharmaceuticals is recalling one lot of Levothyroxine Sodium Tablets, USP, 25 mcg due to subpotency — meaning the tablets contain less active ingredient than labeled. This affects Lot N02212 with an expiration date of 07/2026. Patients taking subpotent levothyroxine may not receive the full intended dose of this thyroid hormone replacement medication.
ModerateFDAJul 29, 2026Major Pharmaceuticals12 products
- Precision Dose glycopyrrolate solution recalled for impurity
Precision Dose Inc. is recalling one lot of Glycopyrrolate Oral Solution (1 mg/5 mL) due to an unidentified impurity found during routine stability testing that does not meet specification. The affected lot (506033) expires November 30, 2026. This medication is prescription-only and supplied in unit-dose oral syringes.
ModerateFDAJul 29, 2026Precision Dose2 products
- BD ChloraPrep Clear recalled for packaging seal defect
BD ChloraPrep Clear, a sterile skin antiseptic solution used before medical procedures, may have open or incomplete seals on individual applicator packaging. This could allow contamination of the sterile product. The issue affects multiple lot numbers distributed nationwide.
ModerateFDAJul 22, 2026CareFusion
- Chiesi CLEVIPREX injection recalled for sterility concerns
Chiesi USA is recalling specific lots of CLEVIPREX (clevidipine) injectable emulsion because the manufacturer cannot guarantee the vials are sterile. This affects vials distributed nationwide with lot numbers 1239521 and 1237454, expiring in October 2027. No injuries have been reported.
ModerateFDAJul 22, 2026Chiesi
- Carbamide peroxide ear drops recalled for low potency
Bell Pharmaceuticals is recalling 11 carbamide peroxide 6.5% ear drop products, all 0.5 fl oz (15 mL), sold under store and pharmacy brands. Testing found the drops contain far less active ingredient than the label states, and their acidity is also off. No injuries have been reported.
ModerateFDAJul 22, 2026Bell Pharmaceuticals11 products
- Padagis Nystatin Cream recalled for reduced potency
Padagis Nystatin Cream USP (100,000 units, 15 g tube, lot #205060, expiring 09/30/2027) has been recalled because stability testing found the active ingredient fell below the required strength specification. The cream may not work as effectively as intended to treat fungal infections.
ModerateFDAJul 22, 2026Padagis